Article
Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
2022-07-15
Abstract excerpt
KRAS is mutated in approximately 25% of cancer patients and first approved KRAS G12C-specific inhibitors showed promising responses. Pancreatic cancer has the highest frequency of KRAS mutations but the prevailing KRAS G12D mutation is difficult to target. Inhibition of the GTP exchange factor (GEF) SOS1 – KRAS interaction impairs oncogenic signaling independently of the specific KRAS mutations. In general, cell l...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a5f9ff1d-2e86-525d-86fb-0c4e581f11b3
- DOI
- 10.21203/rs.3.rs-1791269/v1